Metal-based drugs that break the rules

Cisplatin and other platinum compounds have had a huge impact in the treatment of cancers and are applied in the majority of anticancer chemotherapeutic regimens. The success of these compounds has biased the approaches used to discover new metal-based anticancer drugs. In this perspective we highlight compounds that are apparently incompatible with the more classical (platinum-derived) concepts employed in the development of metal-based anticancer drugs, with respect to both compound design and the approaches used to validate their utility. Possible design approaches for the future are also suggested.


Published in:
Dalton Transactions, 45, 8, 3201-3209
Year:
2016
Publisher:
Cambridge, Royal Soc Chemistry
ISSN:
1477-9226
Laboratories:




 Record created 2016-04-01, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)